Nevertheless, whether these drugs could exert therapeutic effects on breast cancer by inhibiting the over-expression of RRM2, CDK1 and CCNA2, or whether CCNB2, BUB1B and CDC20 are promising therapeutic targets still need to be supported by further research. Here, RRM2 is linked to breast cancer.